Extracorporeal Co2 Removal Market Scope And Analysis

Report Code : TIPMD00002259
Category : Life Sciences

No. of Pages : 150

Buy Now

Extracorporeal CO2 Removal Devices Market Scope, Analysis, and Trends by 2030

Buy Now

Extracorporeal CO2 Removal Devices Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 99.93 Million
Market Size by 2030	US$ 170.54 Million
Global CAGR (2022 - 2030)	6.9%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Product Extracorporeal CO2 Devices and Consumables By Application Acute Respiratory Distress Syndrome Chronic Obstructive Pulmonary Disease By End User Hospitals and Clinics Ambulatory Surgical Centers
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Getinge ALung Technologies Inc Estor NovaLung GmbH Hemodec Baxter Healthcare Eurosets LivaNova Medtronic

Industry Developments and Future Opportunities:

The extracorporeal CO2 removal devices market forecast can help stakeholders in this marketplace plan their growth strategies. A few strategic developments by leading players operating in the market are listed below:

In October 2022, ALung Technologies evaluated the safety and effectiveness of using the hemolung respiratory assist system (RAS) for low-flow extracorporeal CO2 removal (ECCO2R) as an alternative or adjunct to invasive mechanical ventilation for patients requiring respiratory support due to acute exacerbations of chronic obstructive pulmonary disease (COPD).
In March 2022, Respira Labs, a US-based respiratory health technology company, launched Sylvee. This AI-powered wearable lung monitor uses acoustic resonance to assess lung function and identify lung volume fluctuations. It can help detect and treat chronic obstructive pulmonary disease, asthma, and COVID-19.
In May 2021, ALung Technologies, Inc. received FDA clearance for its next-generation Hemolung RAS extracorporeal CO2 removal system, designed to provide respiratory support to patients with acute respiratory failure.
In May 2020, ALung Technologies, Inc. announced the commercial development of the next-generation artificial lung called the hemolung RAS.

Competitive Landscape and Key Companies:

Getinge, ALung Technologies, Inc.; Estor, NovaLung GmbH, Hemodec, Baxter Healthcare, Eurosets, LivaNova, Medtronic, and Xenios AG are among the prominent companies profiled in the extracorporeal CO2 removal devices market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide.